Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22


Vaccination of Young Women Decreases Human Papillomavirus Transmission in Heterosexual Couples: Findings from the HITCH Cohort Study.

Wissing MD, Burchell AN, El-Zein M, Tellier PP, Coutlée F, Franco EL.

Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1825-1834. doi: 10.1158/1055-9965.EPI-19-0618. Epub 2019 Sep 5.


Letter to the editor: The population attributable risk of cancers for inadequate physical activity in Canada in 2015.

Wissing MD.

Prev Med. 2019 Sep;126:105747. doi: 10.1016/j.ypmed.2019.06.005. No abstract available.


Human Papillomavirus Viral Load and Transmission in Young, Recently Formed Heterosexual Couples.

Wissing MD, Louvanto K, Comète E, Burchell AN, El-Zein M, Rodrigues A, Tellier PP, Coutlée F, Franco EL.

J Infect Dis. 2019 Aug 30;220(7):1152-1161. doi: 10.1093/infdis/jiz238.


Short- and long-term survival has improved after radical cystectomy for bladder cancer in Québec during the years 2000-2015.

Wissing MD, Santos F, Zakaria AS, O'Flaherty A, Tanguay S, Kassouf W, Aprikian AG.

J Surg Oncol. 2019 Jun;119(8):1135-1144. doi: 10.1002/jso.25456. Epub 2019 Mar 28.


Improving the reporting of cancer-specific mortality and survival in research using cancer registry data.

Wissing MD, Greenwald ZR, Franco EL.

Cancer Epidemiol. 2019 Apr;59:232-235. doi: 10.1016/j.canep.2019.02.004. Epub 2019 Mar 2.


Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada.

Wissing MD, Chevalier S, O'Flaherty A, McKercher G, Aprikian S, Saad F, Carmel M, Lacombe L, Hamel M, Aprikian A.

Psychooncology. 2019 Apr;28(4):839-846. doi: 10.1002/pon.5031. Epub 2019 Feb 27.


Postoperative Pelvic Radiotherapy in Patients With Endometrial Cancer May Increase the Risk for Secondary Pelvic Cancers: A Post Hoc Analysis of Results From the TME, PORTEC-1, and PORTEC-2 Trials.

Wissing MD, Azoulay L.

J Clin Oncol. 2017 Jun 1;35(16):1861-1862. doi: 10.1200/JCO.2017.72.6497. Epub 2017 Mar 13. No abstract available.


Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?

Greenwald ZR, Huang LN, Wissing MD, Franco EL, Gotlieb WH.

Cancer. 2017 May 1;123(9):1545-1554. doi: 10.1002/cncr.30529. Epub 2016 Dec 27.


Chemotherapy- and irradiation-induced bone loss in adults with solid tumors.

Wissing MD.

Curr Osteoporos Rep. 2015 Jun;13(3):140-5. doi: 10.1007/s11914-015-0266-z. Review.


Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.

Wissing MD, De Morrée ES, Dezentjé VO, Buijs JT, De Krijger RR, Smit VT, Van Weerden WM, Gelderblom H, van der Pluijm G.

Oncotarget. 2014 Sep 15;5(17):7357-67.


CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H.

Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3.


Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.

Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, Kortenhorst MS, Gerber S, Rosen M, Shaikh F, Zahurak ML, Rudek MA, Hammers H, Rudin CM, Carducci MA, Kachhap SK.

Cancer Med. 2014 Oct;3(5):1322-35. doi: 10.1002/cam4.289. Epub 2014 Jul 3.


Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.

Wissing MD, Kluetz PG, Ning YM, Bull J, Merenda C, Murgo AJ, Pazdur R.

Cancer. 2014 Oct 1;120(19):3025-32. doi: 10.1002/cncr.28809. Epub 2014 Jun 25.


Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression.

Wissing MD, Dadon T, Kim E, Piontek KB, Shim JS, Kaelber NS, Liu JO, Kachhap SK, Nelkin BD.

Oncol Rep. 2014 Jul;32(1):419-24. doi: 10.3892/or.2014.3174. Epub 2014 May 13.


Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.

Wissing MD, van Leeuwen FW, van der Pluijm G, Gelderblom H.

Clin Cancer Res. 2013 Nov 1;19(21):5822-7. doi: 10.1158/1078-0432.CCR-13-1896. Epub 2013 Sep 19. Review.


Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.

Wissing MD, Mendonca J, Kortenhorst MS, Kaelber NS, Gonzalez M, Kim E, Hammers H, van Diest PJ, Carducci MA, Kachhap SK.

FASEB J. 2013 Oct;27(10):4279-93. doi: 10.1096/fj.12-222893. Epub 2013 Jul 24.


Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.

Kortenhorst MS, Wissing MD, Rodríguez R, Kachhap SK, Jans JJ, Van der Groep P, Verheul HM, Gupta A, Aiyetan PO, van der Wall E, Carducci MA, Van Diest PJ, Marchionni L.

Epigenetics. 2013 Sep;8(9):907-20. doi: 10.4161/epi.25574. Epub 2013 Jul 19.


Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.

Wissing MD, van Oort IM, Gerritsen WR, van den Eertwegh AJ, Coenen JL, Bergman AM, Gelderblom H.

Clin Genitourin Cancer. 2013 Sep;11(3):238-250.e1. doi: 10.1016/j.clgc.2013.04.004. Epub 2013 May 6.


Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.

Wissing MD, van Diest PJ, van der Wall E, Gelderblom H.

Expert Opin Investig Drugs. 2013 May;22(5):635-61. doi: 10.1517/13543784.2013.789858. Review.


Tales of how great drugs were brought down by a flawed rationale--letter.

Wissing MD, Carducci MA, Gelderblom H, van Diest PJ.

Clin Cancer Res. 2013 Mar 1;19(5):1303. doi: 10.1158/1078-0432.CCR-12-2695. Epub 2013 Feb 7. No abstract available.


Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells.

Wissing MD, Mendonca J, Kim E, Kim E, Shim JS, Kaelber NS, Kant H, Hammers H, Commes T, Van Diest PJ, Liu JO, Kachhap SK.

Cancer Biol Ther. 2013 May;14(5):401-10. doi: 10.4161/cbt.23759. Epub 2013 Feb 1.


Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor.

Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M, Shabbeer S, Mendonca J, Deangelis J, Marchionni L, Lin J, Höti N, Nortier JW, DeWeese TL, Hammers H, Carducci MA.

PLoS One. 2010 Jun 18;5(6):e11208. doi: 10.1371/journal.pone.0011208.

Supplemental Content

Loading ...
Support Center